Proposed are medicinal products in the form of modified release formulations comprising the drug substance (-)-(3aR,4S,7aR)-4-hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such medicinal products. The medicinal products are useful in treating patients suffering from Parkinson's disease and exhibiting L-dopa induced dyskinesia.
展开▼
